SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 104.09-1.3%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (2808)12/13/2012 9:55:03 PM
From: tommysdad  Read Replies (1) of 3202
 
Pfizer has published and spoken quite a bit about tofa, but I don't think they have addressed BBB. I don't see PgP data, either. However, it being small, not particularly lipophilic, and a very low dose in the clinic, leads me to believe PgP isn't an issue. The volume of distribution in pre-clinical species is moderate. Add all that up and it's a decent bet it gets into the brain. That project team did a damn fine job.

INCY's molecules are analogues of tofa, so they are likely pretty similar. But there is less public data on those two. Both are a bit more lipophilic, probably have higher volumes. (probably)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News